Annweshan is a spin-off based on NCL ‘s technology created under Venture Center’s “Lab2Mkt” program. The company wishes to develop innovative health care & biotech products at affordable costs and commercialize these products. Currently Annweshan is working to develop a metabolite (non-nucleic acid) biomarker based novel TB diagnostic kit for sensitive (can detect MTB missed by smear microscopy), specific (to MTB in sputum samples), fast, easy, instrument- free, cheap and point-of-care detection of M. tuberculosis bacilli in patient’s sputum as well as severity of disease in patients. The company has received Biotechnology Ignition Grant by DBT-BIRAC, GoI